Introduction
Acute coronary syndrome (ACS) is an umbrella term referring to any group of clinical symptoms compatible with acute myocardial ischemia. It gives rise to a spectrum of clinical manifestations ranging from unstable angina (UA) to ST-segment elevation myocardial infarction (STEMI). Despite considerable progresses in the field of ACS have been made, correctly identifying ACS among patients presenting to the emergency department (ED) with chest pain is an unmet goal. Actually, acute myocardial infarction (AMI) diagnosis is adjudicated in < 20% of admissions at ED for suspected ACS [1] , so that the majority of patients are incorrectly hospitalized. On the other hand, the mortality for post-ACS events/pathologies remains high. Up to 30% of patients leaving hospital after ACS event is re-admitted within the first 6-months [2] . In a large US registry consisting of 60.6500 patients with AMI, HF was identified in 20% of patients on admission, with a further 8.6% developing HF during hospitalization [3] . Therefore, identifying reliable biomarkers to improve risk stratification and enhancing patient outcome prediction remains a challenge. The research in the field of biochemical markers for ACS is thriving at present.
Over the past years biomarkers have become a fundamental tool for the evaluation, from diagnosis to prognosis and treatment, of numerous diseases, including ACS.
Manifold biomarkers have been considered as a useful tool in ACS patients [4] [5] [6] [7] [8] . A crucial role for inflammation in the pathogenesis of atherosclerosis has emerged in the past decade, so researchers have focused their attention on the potential role of pro-inflammatory markers in ACS. Among these, Gal-3 has been recently investigated. Although it has been validated as an independent prognostic biomarker in both acute and chronic heart failure (HF) and it has been proposed to predict HF and all-cause mortality in the general population, its precise role in ACS has not yet been fully clarified [9] [10] [11] .
This article will review current knowledge about Galectin-3 in patients with ACS.
repair, response to infection, lung, kidney and liver disease, and many other conditions [13] . Under certain conditions, as ischemic injury, Gal-3 is over-expressed in attempt to regulate and maintain cell survival [14] . Finally, Gal-3 is involved in adverse cardiac remodeling and fibrosis; particularly, it has been shown that Gal-3 induces cardiac fibroblasts to proliferate and deposit type I collagen in the myocardium [15, 16] .
Galectin-3 and atherosclerosis
Gal-3 has been linked to atherosclerosis, a chronic inflammatory disease, whose main complication is thrombosis, with local occlusion or distal embolism. This disease process, known as atherothrombosis, can lead to ACS or stroke [17] [18] [19] . The influence of Gal-3 on both atherosclerotic plaque formation and destabilization has been confirmed in several studies [20] [21] [22] .
The role of Gal-3 in atherogenesis is supported by in vivo and in vitro findings. MacKinnon et al. have shown that pharmacological inhibition of Galectin-3 in a well-characterized mouse model of atherosclerosis reduces the plaque development [23] . Indeed, Gal-3 is known to propagate vascular inflammation by supporting monocyte migration in the vascular wall, thus acting as a chemo-attractant; furthermore, the lectin might skew macrophage subtypes polarization toward M1 phenotype, which is considered pro-atherogenic and associated with plaque instability [24, 25] . However, these findings require additional investigations.
Gal-3 propagates inflammation mainly inducing the expression of pro-inflammatory mediators by macrophages. Nevertheless, some Authors [26, 27] suggested that Gal-3 can influence modified-LDL uptake by macrophages; particularly, Gal-3 has been demonstrated to play a major role in transforming macrophages into foam cells, which secrete Gal-3, attracting monocytes and macrophages. However, Gal-3 might influence plaque progression also avoiding the effective removal of modified lipoproteins, as shown by Iacobini in an experimental study in mice [28] . As suggested by an in vitro study, another observation supporting the pro-atherogenic role of Gal-3 is its binding with Lipopolysaccharide (LPS), which in turn exerts several pro-atherogenic effects [29] . Finally, a pivotal process that contributes to plaque instability and progression of the atherosclerotic lesions is the phenotypic change of vascular smooth muscle cells (VSMCs) from a differentiated state to a dedifferentiated state. In vitro experiments have shown Gal-3 is involved in the phenotypic transformation of VSMCs [30] .
Due to the above-mentioned mechanisms, Gal-3 has been proposed as a biomarker for progression and destabilization of atherosclerotic plaques [31, 32] .
Gal 3 in ACS
Given such evidence, Gal-3 has been investigated in ACS patients, especially in MI setting.
Firstly, the most common finding among such investigations is that circulating Gal-3 levels are elevated in ACS/AMI, being released during the acute phase of AMI [31, [33] [34] [35] [36] [37] [38] [39] . Indeed, Gal-3 could be part of a survival mechanism of the injured myocardium to cope with the ischemic insult [14] . Several evidences have pointed out Gal-3 is not a simple bystander but it represents an important player in the cardiac remodeling process following MI. Noteworthy, it has a different and controversial role in early and late phases. In vivo model of MI have revealed that Gal-3 is expressed by cardiomyocytes and endothelial cells within the first hours of ischemia and regulates survival in cardiomyocytes probably through its anti-apoptotic activity [14] . Moreover, in early phases it contributes actively to the reparative processes in the infarcted area, which are essential for the maintenance of ventricular function after MI. On the contrary, in the later phase, Gal-3 could support the transition from acute to chronic inflammation and trigger cardiac fibrosis leading to adverse ventricular remodeling and, finally, heart failure [40] (Fig. 1) .
So far, only Lisowska et al. and George et al. have compared Gal-3 levels in NSTEMI and STEMI patients achieving contrasting data. While Lisowska et al. found no significant difference, on the contrary, higher Gal-3 concentrations were observed in STEMI compared to NSTEMI patients by George et al. [8, 41] . However, most of the studies have been conducted on STEMI patients only, so it was no possible to investigate the potential differences of Gal-3 between STEMI and NSTEMI.
Gal-3 and Troponin
Troponins are currently the gold standard for the detection of myocardial injury and have a pivotal role in ACS diagnosis. Some Authors compared Gal-3 and Troponin at baseline in patients with ACS, achieving contrasting results. Singsaas et al., when studying 38 STEMI, 
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Clinical Biochemistry 50 (2017) [797] [798] [799] [800] [801] [802] [803] 52 previous complicated MI patients and 22 healthy controls, found Gal-3 levels were increased in both MI groups than controls and it correlated with TnT only in previous MI patients but not in STEMI [42] . Similarly, Lisowska et al. in a larger cohort of MI patients including 143 STEMI and 90 NSTEMI patients, found no significant correlation between Gal-3 and TnI on admission [8] . Oppositely, Bivona et al. in a group of MI patients (125 STEMI and 90 NSTEMI), found a correlation between Gal-3 and hsTnI on admission (r = 0.2; p < 0.001), but not after 5 days [37] . Probably, Gal-3 and Troponin reflect two relevant but different pathogenic pathways following ACS; Gal-3 is a marker of inflammation and fibrosis while Troponin is a marker of myocardial necrosis. Thus, it is conceivable the coexistence of both biomarkers during early acute phase of ACS.
Kinetics of Gal-3
So far, few Authors investigated the kinetic of Gal-3 following MI. First, Milner et al. reported that Gal-3 levels change following a STEMI according to timing of reperfusion [43] . They found Gal-3 to be elevated in patients immediately after STEMI and significantly decreased within 24 h proportionally with increasing time since reperfusion. Indeed, when patients were stratified according to timing of primary percutaneous coronary intervention (pPCI) from onset of pain, Gal-3 concentrations were significantly lower in "early reperfusion" group vs "late reperfusion" group. Similarly, Bivona et al. reported Gal-3 levels were elevated immediately after AMI and decreased significantly within 5 days after the acute event [37] . Moreover, they observed a trend of decrease in Gal-3 levels between patients undergoing pPCI and those treated with medication only. Also Lisowska et al. analyzed the kinetics of Gal-3 at baseline and after 5 days but achieving opposite results [8] . They did not observe differences in Gal-3 levels within 5 days after AMI. Additional studies in larger cohorts are required to clarify the pattern of plasma Galectin-3 expression following MI.
Gal-3 and prognosis
Several Authors have investigated the potential prognostic role of Gal-3 in ACS patients (Table 1) . MI causes complex alterations in the architecture and function of the left ventricle (LV), named "LV remodeling" (LVR), involving both the infarcted and non-infarcted myocardium [44] . LVR occurs initially as a compensatory mechanism but later it can lead to adverse LVR resulting in LV dysfunction and HF. Indeed, LVR represents an important predictor of mortality and HF after MI [45] . Weir et al. first explored the relationship between Gal-3 and LVR concluding that elevated baseline plasma Gal-3 levels are associated with lower left ventricular ejection fraction (LVEF), a wellknown indicator of poor outcome being associated to adverse LVR, at 24-weeks follow-up, but no at baseline, in patients with MI [34] . In the same year, Tsai et al. showed a significant inverse correlation between Gal-3 and LVEF in STEMI patients treated by pPCI [33] . Most importantly, they found high Gal-3 levels were an independent predictor of 30-day major adverse clinical outcomes (MACO) among STEMI patients. Similarly, van der Velde found that high baseline Gal-3 levels to be associated with a lower LVEF and a larger infarct size in acute STEMI patients underwent pPCI at 4 months follow-up [46] . Also Mayr et al. investigated the correlation between Gal-3 with infarct size and LVEF in reperfused STEMI patients after 4 months [57] . They failed to find a correlation between Gal-3 and LVEF, but documented a significant correlation between Gal-3 and infarct size (r:0.406, P: 0.036). However, these results are limited by the small size of the study sample (29 STEMI patients). In another small cohort consisting of 26 STEMI patients, Perea et al. concluded Gal-3, measured early after MI, is an independent predictor of LV remodeling at 6-month follow-up [48] . In particular, they assessed LV remodeling with extracellular volume fraction (ECV), determined by cardiovascular magnetic resonance (CMR). In a larger cohort comprising 103 STEMI patients treated by pPCI, Di Tano et al. found Gal-3 is an independent predictor of LVR after MI [49] . LVR was defined as a ≥ 15% increase in LV end-systolic volume. They observed LVR + patients had higher Gal-3 levels compared to LVR-patients at baseline, 1 and 6 months. Finally, George et al. observed a significant association between high Gal-3 levels and lower LVEF in a cohort of ACS patients [41] . Likewise, Ipek et al. in ACS patients found a negative correlation between Gal-3 levels and LVEF [36] . Furthermore, these Authors showed a strong correlation between Gal-3 and the severity of coronary artery disease assessed by Gensini score. Thus, they concluded Gal-3 could be useful in clinical practice to identify high-risk patients, especially in NSTEMI setting. However, their study population was too small and larger prospective studies are required to confirm their findings.
Oppositely to above-mentioned findings, Singsaas found only in patients with previous MI, but not in patients with acute STEMI, a significant association between Gal-3 and infarct size or LV volumes, both determinant of adverse LVR after MI and important predictor of adverse cardiovascular events [42] . Thus, in contrast to aforementioned data, they found Gal-3 was useful for risk stratification in patients with previous MI but no acute MI. However, selection bias and biological heterogeneity due to relatively small sample size of their study could have influenced their findings.
Some Authors evaluated the potential role of Gal-3 as a predictive marker of mortality, HF, atrial fibrillation (AF) and re-infarction in ACS patients [8, 33, 38, [50] [51] [52] .
As described above, Tsai et al. showed that circulating Gal-3 is a strong independent predictor of the combined 30-day MACO, defined as advanced congestive heart failure (CHF) and 30-day mortality (p < 0.0001), in STEMI patients undergoing pPCI [33] . Lisowska et al. reported Gal-3 to predict mortality in mid-term follow-up of patients after AMI [8] . In particular, study population included 143 STEMI, 90 NSTEMI, 100 stable CAD and 100 healthy controls; the median follow-up period in AMI group was 2.8 years. Multivariate logistic regression analysis showed that Gal-3 > 8.7 ng/ml predicts the all-cause mortality after AMI (OR = 7.92, 95% CI: 1.75-35.8, p = 0.007). The Authors concluded that Gal-3 measured within 24 h after admission is independently related to death within 3 years. In a large trial on STEMI patients, O'Donhogue et al. reported the association of increasing Gal-3 levels and the risk of cardiovascular death or HF at 30 days (OR 1.50, 95% 1.24-1.82; p < 0.001); however, this association didn't remain significant after adjusting for traditional risk factors [50] .
Grandin et al. performed a nested case-control study with prospectively collected samples and outcomes from the main biomarker substudy of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVEIT-TIMI 22) TRIAL [38] . The Authors followed up patients for a mean of 2 years, founding that patients who developed HF after ACS have had higher Gal-3 levels compared to those who did not. In this study, Gal-3 was measured within 7 days from the acute event. As Gal-3 levels above the median value were associated with increased risk for the development of HF after ACS independently of clinical risk factors (OR = 2.1, 95% CI 1.2-3.6; p = 0.010), the Authors concluded that Gal-3 could predict the development of HF after AMI.
Finally, elevated Gal-3 concentrations (> 16 ng/mL) have been demonstrated to predict new-onset AF (OR = 5.7, p < 0.05) during hospitalization in acute phase of MI patients treated with pPCI [51] . In the same cohort, the Authors reported Gal-3 might be an independent predictor of re-infarction early after first MI [52] .
The findings of prognostic role of Gal-3 in ACS gained large agreement, excepting for Martin-Reyes et al., who showed Gal 3 to be not an independent predictor of major adverse cardiac events (MACE) in patients attending 1 out of 4 centers participating to the Biomarkers in Acute Coronary Syndrome (BACS) study and in the Biomarkers in Table 1 Studies investigated the prognostic role of Gal-3 in ACS patients. Authors
Study design
Study population

Main findings
Ref.
Weir et al.
Randomized trial 100 AMI patients
Higher Gal-3 levels are associated with lower LVEF at 24-week follow-up.
[34]
Tsai et al.
Case-control 196 STEMI patients and 30 healthy volunteers
Significant negative correlation between Gal-3 levels and LVEF. Moreover, elevated Gal-3 concentrations are a strong independent predictor of 30-day MACO (p < 0.0001) [33] Van der Velde et al. Retrospective
STEMI patients treated with pPCI
Gal-3 taken immediately after MI predicts LVEF and infarct size after 4 months. Elevated Gal-3 levels at baseline has strong association with progressive cardiac remodeling after MI.
[46]
Mayr et al.
Prospective 29 STEMI patients treated with pPCI
A significant association of serum Gal-3 levels and infarct size, after 4 months and a trend, but not statistically significant, correlation of Gal-3 and LVEF.
[47]
Perea et al.
Prospective 26 STEMI patients
Gal-3 measured acutely after STEMI is an independent predictor of LVR at 6 month followup [48] Di tano et al.
Prospective 103 STEMI patients treated by pPCI Elevated Gal-3 levels at baseline are an independent predictor of LVR at 6 month follow-up [49] George et al. No association between Gal-3 and heart failure [4] MI, myocardial infarction; STEMI, ST-Segment Elevation Myocardial Infarction; N-STEMI, non-ST segment elevation myocardial infarction; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; MACO, major adverse clinical outcome; pPCI, primary percutaneous coronary intervention; LVR, left ventricular remodeling; ACS, acute coronary syndrome; CSA, chronic stable angina; MVA, microvascular angina; HF, heart failure; UA, unstable angina; AF, atrial fibrillation.
Acute Myocardial Infarction (BAMI) study [4] . The Authors studied 270 post-AMI patients during a 6 months follow-up period, in aim to assess the relationship between the Syntax Score and the coronary artery calcification, and to identify biomarkers involved in atherogenesis and calcification processes. None of the biomarkers, including Gal-3, was found to predict outcome, including heart failure, in these patients. To note that plasma determination was performed six months after the enrolment, in an outpatient setting.
Gal-3 as target for therapeutic strategies
Given the observations that Gal-3 has a pivotal role in pathophysiology of adverse cardiac remodeling and it is an independent predictor of HF after ACS, it is reasonable to hypothesize that therapies inhibiting Gal-3 might influence HF progression in high-risk ACS patients [53, 54] (Fig. 1) . The current American and European guidelines recommend a mineralocorticoid receptor antagonist (MRA) for treatment of AMI patients with LV dysfunction (≤ 40%) and HF symptoms [55, 56] . Indeed, MRAs (eplerenone and spironolactone) have a cardioprotective effect reducing post-infarction collagen synthesis and progressive cardiac remodeling [57, 58] . In an experimental model of left ventricular systolic dysfunction after AMI, Lax et al. have shown MRAs down-regulated Gal-3 expression in the myocardium after AMI and such regulation correlated with lower expression levels of fibrosis and inflammatory markers including collagen type I, collagen III and TNF-α [59] . Thus, Authors suggest Gal-3 measurements could be helpful for guiding the use of MRA therapy. Nevertheless, a clinical study by Weir et al. did not confirm such association. They found no favorable effects of eplerenone on plasma Gal-3 levels over 24 weeks in patients after AMI [34] . A possible explanation for the conflicting findings of clinical and experimental studies lies in the observation that myocardial and serum concentrations of Gal-3 do not always correlate [60] .
Also Modified Citrus Pectin (MCP) and N-acetyllactosamine (N-Lac) have been investigated in relation to Galectin-3 inhibition and they have been found to attenuate cardiac fibrosis. MCP, an oligosaccharide present in the peels of fruits and vegetables belonging to Pectin family, inhibits Gal-3 by binding to its CRD domain. In experimental models, MCP was shown to reduce collagen I synthesis and N-Lac to downregulate collagen production, processing, cleavage, cross-linking and deposition [53, 61] . Despite preclinical investigations seems to encourage the use of Gal-3 inhibitors to prevent or reduce maladaptive remodeling and, consequently, HF in patients following MI, additional experimental studies and clinical trials are undoubtedly warranted. It is a challenge to test whether Gal-3 concentrations could be useful to identify ACS patients at high risk for HF and, thus, candidate for specific therapeutic intervention.
Galectin-3 assays
To translate experimental findings of circulating biomarkers into clinical practice, the use of reliable and highly standardized assays on automated platforms is a prerequisite. Generally, antibody-based tests are the primary technology used for clinical measurement of cardiac biomarkers in peripheral circulation. In literature, the majority of published clinical studies measured circulating Gal-3 by a manual Food and Drug Administration (FDA) -approved assay, named BG Medicine Galectin-3. However, the most recent studies have been performed on automated assays. Both manual and automated assays employ the same monoclonal antibodies and conjugate. Table 2 provides analytical information on commercially available assays for Gal-3 measurement in human serum/plasma. All assays can be performed on serum or EDTA plasma. Hemolysis produce a false increase of Gal-3 levels so hemolyzed specimen should be discarded. Gal-3 is stable for nine freeze-thaw cycles after storage at −20°C or − 70°C [62] .
Both ARCHITECT and VIDAS assays show measurement range comparable to BGM with shorter turnaround times, so they represent a rapid, easy and reliable tools to measure circulating Galectin-3. Galectin-3 measurement on automated platforms is attractive for daily routine because it can be tested in parallel with several other standard blood tests such as hematology, chemistry or other cardiac markers.
Conclusions
The exact role of Gal-3 in pathobiology of ACS is still unknown, but many efforts have been done in order to understand how Gal-3 influences the development of ACS. Despite evidence showing Gal-3 to play a part in the early acute phase of AMI, it is clearly not a predictive or a diagnostic marker for ACS. It seems sound to clearly define Gal-3 as a clinical biomarker due to its proved prognostic value in ACS. Indeed, the most common finding in such studies reviewed is that Gal-3 has a good prognostic value in ACS, in terms of occurrence of HF, cardiovascular death and all-cause mortality. Additionally, Gal-3 might represent a target therapy to prevent or reverse the progression of cardiac remodeling. HF as the result of loss of myocardiocytes, fibrosis and cardiac remodeling, represent the most common complication following ACS, occurring in half of patients experienced this condition. Risk assessment of HF in ACS patients is crucial because a strong relationship between the progression of HF and the delay of the diagnosis and therapeutic management has been documented. A multifaceted strategy consisting of clinical, imaging and laboratory investigations seems to be a reliable approach to evaluate HF risk after ACS. The measurement of cardiac troponins and natriuretic peptides, particularly B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and mid-regional atrial natriuretic peptide (MR-proANP), have been endorsed by the most important guidelines and recommendations for diagnosis and management of ACS [63] . Nevertheless, the American College of Cardiology (ACC) and the American Heart Association (AHA) Guideline suggests evaluating the measurement of additional biomarker for additive risk stratification of HF in the hospitalized/acute setting [64] . Several studies have shown encouraging results on Galectin-3 but further investigations are needed to validate its use in the clinical practice alone or as a part of multimarker strategy to improve management and outcome in ACS. A multimarker approach mirroring the different pathways involved in the complex pathophysiology of ACS might increase the diagnostic accuracy of current strategies and identify ACS patients with different phenotypes that might benefit from individualized therapy.
In conclusion, Galectin-3 is emerging as a promising biomarker for outcome prediction and for guidance therapy in patients with ACS. The Authors declare that there is no conflict of interest.
